Skip to main navigation Skip to main content

CMH : Clinical and Molecular Hepatology

OPEN ACCESS
ABOUT
BROWSE ARTICLES
FOR CONTRIBUTORS

Page Path

9
results for

"Geum-Youn Gwak"

Article category

Keywords

Publication year

"Geum-Youn Gwak"

Original Articles

Hepatic neoplasm

Substantial risk of recurrence even after 5 recurrence-free years in early-stage hepatocellular carcinoma patients
Jihye Kim, Wonseok Kang, Dong Hyun Sinn, Geum-Youn Gwak, Yong-Han Paik, Moon Seok Choi, Joon Hyeok Lee, Kwang Cheol Koh, Seung Woon Paik
Clin Mol Hepatol 2020;26(4):516-528.
Published online September 11, 2020
DOI: https://doi.org/10.3350/cmh.2020.0016
Background/Aims
Although hepatocellular carcinoma (HCC) is notorious for its high recurrence rate, some patients do not experience recurrence for more than 5 years after resection or radiofrequency ablation for early-stage HCC. For those with five recurrence-free period, the risk of HCC recurrence within the next 5 years remains unknown.
Methods
A total of 1,451 consecutive patients (median, 55 years old; males, 79.0%; hepatitis B virus-related, 79.3%) with good liver function (Child-Pugh class A) diagnosed with early-stage HCC by Barcelona Clinic Liver Cancer Staging and received radiofrequency ablation or resection as an initial treatment between 2005 and 2010 were analyzed.
Results
During a median follow-up period of 8.1 years, 961 patients (66.2%) experienced HCC recurrence. The cumulative recurrence rates increased to 39.7%, 60.3%, and 71.0% at 2, 5, and 10 years, respectively, and did not reach a plateau. Five years after HCC diagnosis, 487 patients were alive without experiencing a recurrence. Among them, during a median of 3.9 additional years of follow-up (range, 0.1–9.0 years), 127 patients (26.1%) experienced recurrence. The next 5-year cumulative recurrence rate (5–10 years from initial diagnosis) was 27.0%. Male sex, higher fibrosis-4 scores, and alpha-fetoprotein levels at 5 years were associated with later HCC recurrence among patients who did not experience recurrence for more than 5 years.
Conclusions
The HCC recurrence rate following 5 recurrence-free years after HCC treatment was high, indicating that HCC patients warrant continued HCC surveillance, even after 5 recurrence-free years.

Citations

Citations to this article as recorded by  Crossref logo
  • Entinostat suppresses hepatocellular carcinoma metastasis by upregulating AZGP1 through histone acetylation
    Weiguo Cai, Xinru Pei, Xiaodie Ye, Yan Zhai, Na Wu, Ziyi Wang, Wei Lu
    Biochemical Pharmacology.2026; : 117718.     CrossRef
  • Cure after surgery for hepato-pancreato-biliary cancers: A systematic review
    Marianna Maspero, Carlo Sposito, Vincenzo Mazzaferro, Giorgio Ercolani, Alessandro Cucchetti
    Digestive and Liver Disease.2025; 57(1): 1.     CrossRef
  • What Is the Optimal Locoregional Approach for Recurrent Hepatocellular Carcinoma?
    Neil B. Newman, Colin M. Court, Alexander A. Parikh
    Journal of Clinical Oncology.2025; 43(9): 1050.     CrossRef
  • Circulating blood biomarkers for minimal residual disease in hepatocellular carcinoma: A systematic review
    Edoardogregorio Galli, Giorgio Patelli, Federica Villa, Nicole Gri, Chiara Mazzarelli, Iacopo Mangoni, Cristiano Sgrazzutti, Silvia Ghezzi, Andrea Sartore-Bianchi, Luca Saverio Belli, Luciano De Carlis, Angelo Vanzulli, Salvatore Siena, Katia Bencardino
    Cancer Treatment Reviews.2025; 135: 102908.     CrossRef
  • Extrahepatic Recurrence After Surgical Resection of Hepatocellular Carcinoma Without Intrahepatic Recurrence: A Multi-Institutional Observational Study
    Ga Ram You, Shin Young Park, Su Hyeon Cho, Sung Bum Cho, Yang Seok Koh, Chang Hun Lee, Hoon Gil Jo, Sung Kyu Choi, Jae Hyun Yoon
    Cancers.2025; 17(9): 1417.     CrossRef
  • Mesenchymal circulating tumor cells as prognostic markers in HCC Post-Transplantation: Sirolimus as a potential therapeutic Modulator
    Jinyan Chen, Rongsen Wang, Huigang Li, Jiancai Sun, Ruijie Zhao, Jianyong Zhuo, Zuyuan Lin, Chiyu He, Xingzhu Chen, Jun Li, Leyi Chen, Xudong Yang, Xuyong Wei, Shusen Zheng, Xiao Xu, Di Lu
    European Journal of Surgical Oncology.2025; 51(9): 110147.     CrossRef
  • Predictors of long-term survival outcomes of patients with hepatocellular carcinoma without recurrence at five years after liver resection
    Cheng-Ying Hsieh, Chee-Chien Yong, Yueh-Wei Liu, Wei-Feng Li, Chih-Chi Wang, Yi-Hao Yen, Chih-Yun Lin
    Langenbeck's Archives of Surgery.2025;[Epub]     CrossRef
  • Landscape of T-cell exhaustion heterogeneity and HBV integration in virus-related HCC revealed by whole-exome, transcriptome, and single-cell sequencing
    Soon Kyu Lee, Jinyeong Lim, Joo Yeon Jhun, Jeonghyeon Moon, Hye Seon Kim, Jong Young Choi, Ho Joong Choi, Young Kyoung You, Ji Won Han, Pil Soo Sung, Kwon Yong Tak, Seung Kew Yoon, Woong-Yang Park, Mi-La Cho, Jeong Won Jang
    JHEP Reports.2025; 7(11): 101518.     CrossRef
  • Targeting STAT3 by erianin to overcome sorafenib resistance in hepatocellular carcinoma: Integrated network pharmacology with molecular docking, dynamics simulations, and in vitro validation
    Zixian Liu, Ruoning Qian, Yuanchao Feng, Ruogu Qi, Zhengguang Zhang, Fuqiong Zhou
    Biochemical and Biophysical Research Communications.2025; 778: 152348.     CrossRef
  • Relative survival among cancer survivors enrolled in private cancer insurance in Japan, using the internal insurance-enrolled population as the reference
    Makoto Hiraoka, Hayaka Uekusa, Akira Okada, Reiko Inoue, Kayo Ikeda-Kurakawa, Yusuke Otsuka, Daisuke Namiki, Ryuichi Yamamoto, Toshimasa Yamauchi, Masaomi Nangaku, Kazuhiko Ohe, Satoko Yamaguchi, Takashi Kadowaki
    International Journal of Clinical Oncology.2025; 30(11): 2178.     CrossRef
  • Machine Learning‐Based Model for Predicting Recurrence‐Free Survival After Interventional Therapy in Malnourished Hepatocellular Carcinoma Patients
    Ningning Lu, Chunwang Yuan, Bin Sun, Xiongwei Cui, Wenfeng Gao, Yonghong Zhang
    Cancer Medicine.2025;[Epub]     CrossRef
  • Comparative efficacy of postoperative adjuvant transcatheter arterial chemoembolization and hepatic artery infusion chemotherapy in patients with BCLC stage 0-B hepatocellular carcinoma at high risk of recurrence following radical resection
    Xu Feng, Yupei Ao, Jiarui Liu, Jue Yuan, Zhengrong Shi, Chengjia Tang
    Frontiers in Pharmacology.2025;[Epub]     CrossRef
  • Efficacy of postoperative adjuvant hepatic artery infusion chemotherapy for hepatocellular carcinoma in microvascular invasion: a propensity-matched score
    Xu Feng, Xinhua Wu, Kai Chen, Yupei Ao, Zhengrong Shi, Yixuan Gong
    Frontiers in Surgery.2025;[Epub]     CrossRef
  • Non-contrast magnetic resonance imaging for detection of late recurrent hepatocellular carcinoma after curative treatment: a prospective multicenter comparison to contrast-enhanced computed tomography
    Dong Wook Kim, Won Chang, So Yeon Kim, Young-Suk Lim, Jonggi Choi, Jungheum Cho, Jin-Wook Kim, Jai Young Cho, Sun Kyung Jeon, Yun Bin Lee, Eun Ju Cho, Su Jong Yu, Kyung-Suk Suh, Kwang-Woong Lee, Dong Ho Lee
    Clinical and Molecular Hepatology.2025; 31(4): 1285.     CrossRef
  • Microvascular Invasion in Hepatocellular Carcinoma (Hcc): Implications and Strategy
    Andrea Celotti, M. Bonafede, G. Baiocchi, M. Tomasoni, F. Petrelli, M. Bonomi, G. Grizzi
    Current Surgery Reports.2025;[Epub]     CrossRef
  • Current Immunotherapy Strategies and Emerging Biomarkers for the Treatment of Hepatocellular Carcinoma
    Audrey Kapelanski-Lamoureux, Anthoula Lazaris, Nicholas Meti, Peter Metrakos
    Cancers.2025; 17(23): 3870.     CrossRef
  • The therapeutic efficacy of radical resection for hepatocellular carcinoma varies markedly by tumor location: a retrospective real-world study
    Xu Feng, Yi-Qiu Wei, Jia-Rui Liu, Zheng-Rong Shi, Kai Chen, Yong-Shuang Lv
    Frontiers in Pharmacology.2025;[Epub]     CrossRef
  • Serum Tumor Necrosis Factor-alpha Concentration and its Prognostic Implication in Hepatocellular Carcinoma
    Vembi Rizky Fatmawati, Ulfa Kholili, Husin Thamrin, Ricky Indra Alfaray
    Biomolecular and Health Science Journal.2025; 8(2): 105.     CrossRef
  • Comparative effectiveness of several adjuvant therapies for patients with hepatocellular carcinoma with high-risk factors for recurrence after hepatectomy: a systematic review and meta-analysis
    Zejin Zhao, Haizhao Yi, Yue Xiao, Zhiyan Li, Jinlong Liu
    Frontiers in Medicine.2025;[Epub]     CrossRef
  • Mechanism study of oleanolic acid derivative, K73-03, inducing cell apoptosis in hepatocellular carcinoma
    Jiaqi Wang, Chuchu Ma, Zhongyuan Tang, Zhengwu Sun, Eskandar Qaed, Xinming Chi, Jun Wang, Yazeed Jamalat, Zhaohong Geng, Zeyao Tang, Qiying Yao
    Cancer Cell International.2024;[Epub]     CrossRef
  • Machine learning-based model for predicting tumor recurrence after interventional therapy in HBV-related hepatocellular carcinoma patients with low preoperative platelet-albumin-bilirubin score
    Qi Wang, Shugui Sheng, Yiqi Xiong, Ming Han, Ronghua Jin, Caixia Hu
    Frontiers in Immunology.2024;[Epub]     CrossRef
  • Smoking as a Risk Factor for Very Late Recurrence in Surgically Resected Early-Stage Primary Hepatocellular Carcinoma
    Wei-Ru Cho, Chih-Chi Wang, Mu-Jung Tsai, Chih-Che Lin, Yi-Hao Yen, Chien Hung Chen, Yuan-Hung Kuo, Chih-Chien Yao, Chao-Hung Hung, Pao-Yuan Huang, An-Che Liu, Ming-Chao Tsai
    Clinical Medicine Insights: Oncology.2024;[Epub]     CrossRef
  • Tubuloside B, a major constituent of Cistanche deserticola, inhibits migration of hepatocellular carcinoma by inhibiting Hippo-YAP pathway
    Jie Yao, Haoqiang Wan, Jingmei Zhang, Wanying Shen, Xiaofang Wei, Chenyan Shi, Baoru Ou, Dongyu Liu, Lanlan Ge, Jia Fei, Xiaobin Zeng
    Phytomedicine.2024; 129: 155552.     CrossRef
  • Magnetic resonance elastography as a preoperative assessment for predicting intrahepatic recurrence in patients with hepatocellular carcinoma
    Jeong Hyun Lee, Jeong Ah Hwang, Kyowon Gu, Jaeseung Shin, Seungchul Han, Young Kon Kim
    Magnetic Resonance Imaging.2024; 109: 127.     CrossRef
  • Hepatic Arterial Infusion Chemotherapy vs Transcatheter Arterial Chemoembolization as Adjuvant Therapy Following Surgery for MVI-Positive Hepatocellular Carcinoma: A Multicenter Propensity Score Matching Analysis
    Yuhua Wen, Lianghe Lu, Jie Mei, Yihong Ling, Renguo Guan, Wenping Lin, Wei Wei, Rongping Guo
    Journal of Hepatocellular Carcinoma.2024; Volume 11: 665.     CrossRef
  • Bioengineered Organoids Offer New Possibilities for Liver Cancer Studies: A Review of Key Milestones and Challenges
    Abdullah Jabri, Jibran Khan, Bader Taftafa, Mohamed Alsharif, Abdulaziz Mhannayeh, Raja Chinnappan, Alaa Alzhrani, Shadab Kazmi, Mohammad Shabab Mir, Aljohara Waleed Alsaud, Ahmed Yaqinuddin, Abdullah M. Assiri, Khaled AlKattan, Yogesh K. Vashist, Dieter
    Bioengineering.2024; 11(4): 346.     CrossRef
  • Glycemic Burden and Clinical Outcomes of Early Stage Hepatocellular Carcinoma after Curative Treatment
    Hyun Joo Lee, Moon Seok Choi, Byeong Geun Song, Won Seok Kang, Geum Youn Gwak, Myung Ji Goh, Yong Han Paik, Joon Hyeok Lee, Dong Hyun Sinn
    Cancers.2024; 16(15): 2652.     CrossRef
  • TFCP2L1 drives stemness and enhances their resistance to Sorafenib treatment by modulating the NANOG/STAT3 pathway in hepatocellular carcinoma
    Dongbo Qiu, Tiantian Wang, Yi Xiong, Kun Li, Xiusheng Qiu, Yuan Feng, Qinghai Lian, Yunfei Qin, Kunpeng Liu, Qi Zhang, Changchang Jia
    Oncogenesis.2024;[Epub]     CrossRef
  • Stage dependent microbial dynamics in hepatocellular carcinoma and adjacent normal liver tissues
    Hee Eun Jo, Sophallika Khom, Sumi Lee, Su Hyeon Cho, Shin Young Park, Ga Ram You, Hyosin Kim, Nah Ihm Kim, Jae-Ho Jeong, Jae Hyun Yoon, Misun Yun
    Scientific Reports.2024;[Epub]     CrossRef
  • Combining transarterial chemoembolization, radiofrequency ablation, and iodine-125 seed implantation for recurrent hepatocellular carcinoma post-hepatectomy
    Yong Zhong, Li Wang, Weibin Dan, Dan Liang
    Diagnostic and Interventional Radiology.2024;[Epub]     CrossRef
  • Post-operative recurrence of liver cancer according to antiviral therapy for detectable hepatitis B viremia: A nationwide study
    Byungyoon Yun, Sang Hoon Ahn, Juyeon Oh, Jin-Ha Yoon, Beom Kyung Kim
    European Journal of Internal Medicine.2023; 107: 66.     CrossRef
  • Statin use is associated with better post‐operative prognosis among patients with hepatitis B virus‐related hepatocellular carcinoma
    Byungyoon Yun, Sang Hoon Ahn, Juyeon Oh, Jin‐Ha Yoon, Beom Kyung Kim
    European Journal of Clinical Investigation.2023;[Epub]     CrossRef
  • Combining local regional therapy and systemic therapy: Expected changes in the treatment landscape of recurrent hepatocellular carcinoma
    Jing Liang, Yi Bai, Fu-Shuang Ha, Ying Luo, Hui-Ting Deng, Ying-Tang Gao
    World Journal of Gastrointestinal Oncology.2023; 15(1): 1.     CrossRef
  • Correspondence on Letter regarding “Impacts of muscle mass dynamics on prognosis of outpatients with cirrhosis”
    Tae Hyung Kim, Young Kul Jung, Hyung Joon Yim
    Clinical and Molecular Hepatology.2023; 29(1): 173.     CrossRef
  • Abbreviated MRI for Secondary Surveillance of Recurrent Hepatocellular Carcinoma After Presumed Curative Treatment
    Sun Kyung Jeon, Dong Ho Lee, Bo‐Yun Hur, Sae‐Jin Park, Se Woo Kim, Junghoan Park, Kyung‐Suk Suh, Kwang‐Woong Lee, Nam‐Joon Yi, Joon Koo Han
    Journal of Magnetic Resonance Imaging.2023; 58(5): 1375.     CrossRef
  • The Role of Ablative Techniques in the Management of Hepatocellular Carcinoma: Indications and Outcomes
    Asanda Koza, Ricky H. Bhogal, Nicos Fotiadis, Vasileios K. Mavroeidis
    Biomedicines.2023; 11(4): 1062.     CrossRef
  • Comparison of different adjuvant therapy regimen efficacies in patients with high risk of recurrence after radical resection of hepatocellular carcinoma
    Xu Feng, Guo-Ying Feng, Jie Tao, Yu-Pei Ao, Xin-Hua Wu, Shi-Guai Qi, Zheng-Rong Shi
    Journal of Cancer Research and Clinical Oncology.2023; 149(12): 10505.     CrossRef
  • Classification of microvascular invasion of hepatocellular carcinoma: correlation with prognosis and magnetic resonance imaging
    Yoon Jung Hwang, Jae Seok Bae, Youngeun Lee, Bo Yun Hur, Dong Ho Lee, Haeryoung Kim
    Clinical and Molecular Hepatology.2023; 29(3): 733.     CrossRef
  • Autophagy-amplifying nanoparticles evoke immunogenic cell death combined with anti-PD-1/PD-L1 for residual tumors immunotherapy after RFA
    Shushan Zhang, Yongquan Huang, Songying Pi, Hui Chen, Feile Ye, Chaoqun Wu, Liujun Li, Qing Ye, Yuhong Lin, Zhongzhen Su
    Journal of Nanobiotechnology.2023;[Epub]     CrossRef
  • Inflammation-related prognostic markers in resected hepatocellular carcinoma
    Fabio Giannone, Nevena Slovic, Patrick Pessaux, Catherine Schuster, Thomas F. Baumert, Joachim Lupberger
    Frontiers in Oncology.2023;[Epub]     CrossRef
  • A Real-World Comparative Study of Microwave and Radiofrequency Ablation in Treatment-Naïve and Recurrent Hepatocellular Carcinoma
    Soon Kyu Lee, Dong Jin Chung, Se Hyun Cho
    Journal of Clinical Medicine.2022; 11(2): 302.     CrossRef
  • External Validation of the FSAC Model Using On-Therapy Changes in Noninvasive Fibrosis Markers in Patients with Chronic Hepatitis B: A Multicenter Study
    Jae Seung Lee, Hyun Woong Lee, Tae Seop Lim, In Kyung Min, Hye Won Lee, Seung Up Kim, Jun Yong Park, Do Young Kim, Sang Hoon Ahn, Beom Kyung Kim
    Cancers.2022; 14(3): 711.     CrossRef
  • Liver-specific LINC01146, a promising prognostic indicator, inhibits the malignant phenotype of hepatocellular carcinoma cells both in vitro and in vivo
    Xiaoyun Ma, Meile Mo, Chao Tan, Jennifer Hui Juan Tan, Huishen Huang, Bihu Liu, Dongping Huang, Shun Liu, Xiaoyun Zeng, Xiaoqiang Qiu
    Journal of Translational Medicine.2022;[Epub]     CrossRef
  • MicroRNA miR-124-3p suppresses proliferation and epithelial–mesenchymal transition of hepatocellular carcinoma via ARRDC1 (arrestin domain containing 1)
    Qiannan Zhao, Fen Jiang, Hui Zhuang, Yanfeng Chu, Fang Zhang, Chenghong Wang
    Bioengineered.2022; 13(4): 8255.     CrossRef
  • Cost-effectiveness of antiviral therapy in untreated compensated cirrhosis patient with serum HBV–DNA level < 2000 IU/mL
    Hankil Lee, Sungin Jang, Sang Hoon Ahn, Beom Kyung Kim
    Hepatology International.2022; 16(2): 294.     CrossRef
  • Cause of death and cause-specific mortality for primary liver cancer in South Korea: A nationwide population-based study in hepatitis B virus-endemic area
    Bo Hyun Kim, Dahhay Lee, Kyu-Won Jung, Young-Joo Won, Hyunsoon Cho
    Clinical and Molecular Hepatology.2022; 28(2): 242.     CrossRef
  • A Radiomics Model Based on Gd-EOB-DTPA-Enhanced MRI for the Prediction of Microvascular Invasion in Solitary Hepatocellular Carcinoma ≤ 5 cm
    Chengming Qu, Qiang Wang, Changfeng Li, Qiao Xie, Ping Cai, Xiaochu Yan, Ernesto Sparrelid, Leida Zhang, Kuansheng Ma, Torkel B. Brismar
    Frontiers in Oncology.2022;[Epub]     CrossRef
  • L-Selenocysteine induced HepG-2 cells apoptosis through reactive oxygen species-mediated signaling pathway
    Kaiying Zhang, Jingyao Su, Danyang Chen, Binger Lin, Yucan Wu, Yibing Wang, Jiapei Lei, Ruilin Zheng, Bing Zhu, Yinghua Li
    Molecular Biology Reports.2022; 49(9): 8381.     CrossRef
  • A Systematic Pan-Cancer Analysis of YY1 Aberrations and their Relationship with Clinical Outcome, Tumor Microenvironment, and Therapeutic Targets
    Xinghao Fu, Feihong Ji, Qi He, Xinguang Qiu, Fu Wang
    Journal of Immunology Research.2022; 2022: 1.     CrossRef
  • Early extrahepatic recurrence as a pivotal factor for survival after hepatocellular carcinoma resection: A 15-year observational study
    Jae Hyun Yoon, Sung Kyu Choi, Sung Bum Cho, Hee Joon Kim, Yang Seok Ko, Chung Hwan Jun
    World Journal of Gastroenterology.2022; 28(36): 5351.     CrossRef
  • Impacts of muscle mass dynamics on prognosis of outpatients with cirrhosis
    Tae Hyung Kim, Young Kul Jung, Hyung Joon Yim, Joo Won Baik, Sun Young Yim, Young-Sun Lee, Yeon Seok Seo, Ji Hoon Kim, Jong Eun Yeon, Kwan Soo Byun
    Clinical and Molecular Hepatology.2022; 28(4): 876.     CrossRef
  • Prognostic Impact of MAFLD Following Surgical Resection of Hepatitis B Virus-Related Hepatocellular Carcinoma: A Nationwide Cohort Study
    Byungyoon Yun, Sang Hoon Ahn, Juyeon Oh, Jin-Ha Yoon, Beom Kyung Kim
    Cancers.2022; 14(20): 5002.     CrossRef
  • New Evidence of Oral Branched-Chain Amino Acid Supplementation on the Prognosis of Patients With Advanced Liver Disease
    Hankil Lee, Jeong-Ju Yoo, Sang Hoon Ahn, Beom Kyung Kim
    Clinical and Translational Gastroenterology.2022; 13(12): e00542.     CrossRef
  • External validation of CAGE‐B and SAGE‐B scores for Asian chronic hepatitis B patients with well‐controlled viremia by antivirals
    Jung Hyun Ji, Soo Young Park, Won Jeong Son, Hye Jung Shin, Hyein Lee, Hye Won Lee, Jae Seung Lee, Seung Up Kim, Jun Yong Park, Do Young Kim, Sang Hoon Ahn, Beom Kyung Kim
    Journal of Viral Hepatitis.2021; 28(6): 951.     CrossRef
  • Treatment efficacy by hepatic arterial infusion chemotherapy vs. sorafenib after liver-directed concurrent chemoradiotherapy for advanced hepatocellular carcinoma
    Sojung Han, Hye Jin Choi, Seung-Hoon Beom, Hye Rim Kim, Hyein Lee, Jae Seung Lee, Hye Won Lee, Jun Yong Park, Seung Up Kim, Do Young Kim, Sang Hoon Ahn, Kwang-Hyub Han, Jinsil Seong, Jong Yun Won, Beom Kyung Kim
    Journal of Cancer Research and Clinical Oncology.2021; 147(10): 3123.     CrossRef
  • The Prognostic Role of On-Treatment Liver Stiffness for Hepatocellular Carcinoma Development in Patients with Chronic Hepatitis B
    Hye Won Lee, Hyun Woong Lee, Jae Seung Lee, Yun Ho Roh, Hyein Lee, Seung Up Kim, Jun Yong Park, Do Young Kim, Sang Hoon Ahn, Beom Kyung Kim
    Journal of Hepatocellular Carcinoma.2021; Volume 8: 467.     CrossRef
  • Does Neutrophil to Lymphocyte Ratio Have a Role in Identifying Cytokeratin 19-Expressing Hepatocellular Carcinoma?
    Chao-Wei Lee, Sey-En Lin, Ming-Chin Yu, Hao-Wei Kou, Cheng-Han Lee, Tony Kuo, Kuan-Chieh Lee, Hsin-I Tsai
    Journal of Personalized Medicine.2021; 11(11): 1078.     CrossRef
  • Metformin and Dichloroacetate Suppress Proliferation of Liver Cancer Cells by Inhibiting mTOR Complex 1
    Tae Suk Kim, Minjong Lee, Minji Park, Sae Yun Kim, Min Suk Shim, Chea Yeon Lee, Dae Hee Choi, Yuri Cho
    International Journal of Molecular Sciences.2021; 22(18): 10027.     CrossRef
  • Immunological Markers, Prognostic Factors and Challenges Following Curative Treatments for Hepatocellular Carcinoma
    Soon Kyu Lee, Sung Won Lee, Jeong Won Jang, Si Hyun Bae, Jong Young Choi, Seung Kew Yoon
    International Journal of Molecular Sciences.2021; 22(19): 10271.     CrossRef
  • Knockdown of Atg7 suppresses Tumorigenesis in a murine model of liver cancer
    Kyung Joo Cho, Sun Yeong Shin, Hyuk Moon, Beom Kyung Kim, Simon Weonsang Ro
    Translational Oncology.2021; 14(9): 101158.     CrossRef
  • Effect of tenofovir alafenamide vs. tenofovir disoproxil fumarate on hepatocellular carcinoma risk in chronic hepatitis B
    Hye Won Lee, Young Youn Cho, Hyein Lee, Jae Seung Lee, Seung Up Kim, Jun Yong Park, Do Young Kim, Sang Hoon Ahn, Beom Kyung Kim, Soo Young Park
    Journal of Viral Hepatitis.2021; 28(11): 1570.     CrossRef
  • Novel Liver Stiffness-Based Nomogram for Predicting Hepatocellular Carcinoma Risk in Patients with Chronic Hepatitis B Virus Infection Initiating Antiviral Therapy
    Jae Seung Lee, Hyun Woong Lee, Tae Seop Lim, Hye Jung Shin, Hye Won Lee, Seung Up Kim, Jun Yong Park, Do Young Kim, Sang Hoon Ahn, Beom Kyung Kim
    Cancers.2021; 13(23): 5892.     CrossRef
  • New next-generation microwave thermosphere ablation for small hepatocellular carcinoma
    Hideyuki Tamai, Jumpei Okamura
    Clinical and Molecular Hepatology.2021; 27(4): 564.     CrossRef
  • Comparative Effectiveness of Adjuvant Treatment for Resected Hepatocellular Carcinoma: A Systematic Review and Network Meta-Analysis
    Ying Liu, Yuzhu Wang, Xinkun Guo, Yifeng He, Jian Zhou, Qianzhou Lv, Xiaowu Huang, Xiaoyu Li
    Frontiers in Oncology.2021;[Epub]     CrossRef
  • 10,630 View
  • 226 Download
  • 67 Web of Science
  • Crossref

Hepatic neoplasm

The role of scheduled second TACE in early-stage hepatocellular carcinoma with complete response to initial TACE
Jung Hee Kim, Dong Hyun Sinn, Sung Wook Shin, Sung Ki Cho, Wonseok Kang, Geum-Youn Gwak, Yong-Han Paik, Joon Hyeok Lee, Kwang Cheol Koh, Seung Woon Paik, Moon Seok Choi
Clin Mol Hepatol 2017;23(1):42-50.
Published online March 7, 2017
DOI: https://doi.org/10.3350/cmh.2016.0058
Background/Aims
We investigated the outcomes of early-stage hepatocellular carcinoma (HCC) patients who showed a complete response (CR) to initial transarterial chemoembolization (TACE), with a focus on the role of scheduled TACE repetition.
Methods
A total of 178 patients with early-stage HCC who were initially treated with TACE and showed a CR based on the modified Response Evaluation Criteria in Solid Tumors (mRECIST) criteria on one month follow-up computed tomography (CT) were analyzed. Among them, 90 patients underwent scheduled repetition of TACE in the absence of viable tumor on CT.
Results
During a median follow-up period of 4.6 years (range: 0.4-8.8 years), mortality was observed in 71 patients (39.9%). The overall recurrence-free and local recurrence-free survival rates at 1 year were 44.4% and 56.2%. In the multivariable model, scheduled repetition of TACE was an independent factor associated with survival (hazard ratio [95% confidence interval]: 0.56 [0.34-0.93], P=0.025). When stratified using Barcelona clinic liver cancer (BCLC) stage, scheduled repetition of TACE was associated with a favorable survival rate in BCLC stage A patients, but not in BCLC 0 patients.
Conclusions
Scheduled repetition of TACE was associated with better survival for early-stage HCC patients showing a CR after initial TACE, especially in BCLC stage A patients.

Citations

Citations to this article as recorded by  Crossref logo
  • Molecular mechanisms of TACE refractoriness: Directions for improvement of the TACE procedure
    Jiahao Li, Yingnan Liu, Ruipeng Zheng, Chao Qu, Jiarui Li
    Life Sciences.2024; 342: 122540.     CrossRef
  • Local recurrence following complete radiologic response in patients treated with transarterial chemoembolization for hepatocellular carcinoma
    Shamar Young, Tina Sanghvi, Sandeep Sharma, Cameron Richardson, Nathan Rubin, Masters Richards, Donna D'Souza, Siobhan Flanagan, Jafar Golzarian
    Diagnostic and Interventional Imaging.2022; 103(3): 143.     CrossRef
  • Metformin administration is associated with enhanced response to transarterial chemoembolization for hepatocellular carcinoma in type 2 diabetes patients
    Woo Jin Jung, Sangmi Jang, Won Joon Choi, Jaewon Park, Gwang Hyeon Choi, Eun Sun Jang, Sook-Hyang Jeong, Won Seok Choi, Jae Hwan Lee, Chang Jin Yoon, Jin-Wook Kim
    Scientific Reports.2022;[Epub]     CrossRef
  • Research Progress on the Predictive Value of Early Curative Effect after TACE for Hepatocellular Carcinoma
    志祥 刘
    Advances in Clinical Medicine.2022; 12(11): 10342.     CrossRef
  • Prognostic Value of Alpha-Fetoprotein in Patients Who Achieve a Complete Response to Transarterial Chemoembolization for Hepatocellular Carcinoma
    Jae Seung Lee, Young Eun Chon, Beom Kyung Kim, Jun Yong Park, Do Young Kim, Sang Hoon Ahn, Kwang-Hyub Han, Wonseok Kang, Moon Seok Choi, Geum-Youn Gwak, Yong-Han Paik, Joon Hyeok Lee, Kwang Cheol Koh, Seung Woon Paik, Hwi Young Kim, Tae Hun Kim, Kwon Yoo,
    Yonsei Medical Journal.2021; 62(1): 12.     CrossRef
  • Association between Time to Local Tumor Control and Treatment Outcomes Following Repeated Loco-Regional Treatment Session in Patients with Hepatocellular Carcinoma: A Retrospective, Single-Center Study
    Krzysztof Bartnik, Wacław Hołówko, Olgierd Rowiński
    Life.2021; 11(10): 1062.     CrossRef
  • Validation of Pre-/Post-TACE-Predict Models among Patients with Hepatocellular Carcinoma Receiving Transarterial Chemoembolization
    David Sooik Kim, Beom Kyung Kim, Jae Seung Lee, Hye Won Lee, Jun Yong Park, Do Young Kim, Sang Hoon Ahn, Seung Up Kim
    Cancers.2021; 14(1): 67.     CrossRef
  • Refractoriness to transarterial chemoembolization in patients with recurrent hepatocellular carcinoma after curative resection
    Mi Young Jeon, Hye Soo Kim, Tae Seop Lim, Dai Hoon Han, Beom Kyung Kim, Jun Yong Park, Do Young Kim, Sang Hoon Ahn, Gi Hong Choi, Jin Sub Choi, Kwang-Hyub Han, Seung Up Kim, Gianfranco D. Alpini
    PLOS ONE.2019; 14(4): e0214613.     CrossRef
  • Long-Term Efficacy and Safety of Partial Splenic Embolization in Hepatocellular Carcinoma Patients with Thrombocytopenia Who Underwent Transarterial Chemoembolization
    Nam Hee Kim, Hong Joo Kim, Yong Kyun Cho, Hyun Pyo Hong, Byung Ik Kim
    Journal of Korean Medical Science.2019;[Epub]     CrossRef
  • A comparison of carbon ion radiotherapy and transarterial chemoembolization treatment outcomes for single hepatocellular carcinoma: a propensity score matching study
    Shintaro Shiba, Kei Shibuya, Hiroyuki Katoh, Takuya Kaminuma, Masaya Miyazaki, Satoru Kakizaki, Ken Shirabe, Tatsuya Ohno, Takashi Nakano
    Radiation Oncology.2019;[Epub]     CrossRef
  • Association of Sustained Response Duration With Survival After Conventional Transarterial Chemoembolization in Patients With Hepatocellular Carcinoma
    Yaojun Zhang, Mengping Zhang, Minshan Chen, Jie Mei, Li Xu, Rongping Guo, Xiaojun Lin, Jiaping Li, Zhenwei Peng
    JAMA Network Open.2018; 1(6): e183213.     CrossRef
  • 13,182 View
  • 226 Download
  • 13 Web of Science
  • Crossref

Hepatic neoplasm

Clinical significance and predictive factors of early massive recurrence after radiofrequency ablation in patients with a single small hepatocellular carcinoma
Ju-Yeon Cho, Moon Seok Choi, Gil Sun Lee, Won Sohn, Jemma Ahn, Dong-Hyun Sinn, Geum-Youn Gwak, Yong-Han Paik, Joon Hyeok Lee, Kwang Cheol Koh, Seung Woon Paik
Clin Mol Hepatol 2016;22(4):477-486.
Published online December 25, 2016
DOI: https://doi.org/10.3350/cmh.2016.0048
Background/Aims
Radiofrequency ablation (RFA) is one of the most frequently applied curative treatments in patients with a single small hepatocellular carcinoma (HCC). However, the clinical significance of and risk factors for early massive recurrence after RFA—a dreadful event limiting further curative treatment—have not been fully evaluated.
Methods
In total, 438 patients with a single HCC of size ≤3 cm who underwent percutaneous RFA as an initial treatment between 2006 and 2009 were included. Baseline patient characteristics, overall survival, predictive factors, and recurrence after RFA were evaluated. In addition, the incidence, impact on survival, and predictive factors of early massive recurrence, and initial recurrence beyond the Milan criteria within 2 years were also investigated.
Results
During the median follow-up of 68.4 months, recurrent HCC was confirmed in 302 (68.9%) patients, with early massive recurrence in 27 patients (6.2%). The 1-, 3-, and 5-year overall survival rates were 95.4%, 84.7%, and 81.8%, respectively, in patients with no recurrence, 99.6%, 86.4%, and 70.1% in patients with recurrence within the Milan criteria or late recurrence, and 92.6%, 46.5%, and 0.05% in patients with early massive recurrence. Multivariable analysis identified older age, Child-Pugh score B or C, and early massive recurrence as predictive of poor overall survival. A tumor size of ≥2 cm and tumor location adjacent to the colon were independent risk factors predictive of early massive recurrence.
Conclusions
Early massive recurrence is independently predictive of poor overall survival after RFA in patients with a single small HCC. Tumors sized ≥2 cm and located adjacent to the colon appear to be independent risk factors for early massive recurrence.

Citations

Citations to this article as recorded by  Crossref logo
  • Long-Term Analysis of Recurrence Beyond Milan Criteria Following Ablation of Solitary Early-Stage Hepatocellular Carcinoma ≤3 cm in Potentially Transplantable Patients: A Over 10-Year Survival Study
    Shuanggang Chen, Han Qi, Hongtong Tan, Fei Cao, Lin Xie, Tao Huang, Ying Wu, Chunyong Wen, Yujia Wang, Lujun Shen, Weijun Fan
    Journal of Hepatocellular Carcinoma.2025; Volume 12: 205.     CrossRef
  • Investigation into the efficiency and prognostic elements of CT-guided ¹²⁵I particle implantation for liver cancer
    Yuxiao Xia, Quanyu Zhou, Xue Jiang, Wenling Tu, Qian Liu, Liangshan Li, Yuhong Shi
    Cancer Imaging.2025;[Epub]     CrossRef
  • Recurrence patterns and survival outcomes after irreversible electroporation for hepatocellular carcinoma: a 6-year multicenter experience
    Min Xu, Shanyu Yin, Qiyu Zhao, Guo Tian, Jinhua Pan, Gang Dong, Wu Zhang, Tuerganaili Aji, Jiansong Ji, Xinhua Chen, Danxia Xu, Tian’an Jiang
    European Radiology.2025;[Epub]     CrossRef
  • BCLC strategy for prognosis prediction and treatment recommendations: The 2025 update
    Maria Reig, Marco Sanduzzi-Zamparelli, Alejandro Forner, Jordi Rimola, Joana Ferrer-Fàbrega, Marta Burrel, Ángeles Garcia-Criado, Alba Díaz, Neus Llarch, Gemma Iserte, Meritxell Mollà, Robin K. Kelley, Peter R. Galle, Vincenzo Mazzaferro, Riad Salem, Brun
    Journal of Hepatology.2025;[Epub]     CrossRef
  • Prognostic model for predicting recurrence in hepatocellular carcinoma patients with high systemic immune-inflammation index based on machine learning in a multicenter study
    Ningning Lu, Shugui Sheng, Yiqi Xiong, Chuanren Zhao, Wenying Qiao, Xiaoyan Ding, Jinglong Chen, Yonghong Zhang
    Frontiers in Immunology.2024;[Epub]     CrossRef
  • Risk of Treatment Failure and Death after Ablation in Hepatocellular Carcinoma Patients—A Multiparametric Prediction
    Sergio Muñoz-Martínez, Victor Sapena, Ángeles García-Criado, Anna Darnell, Alejandro Forner, Ernest Belmonte, Marco Sanduzzi-Zamparelli, Jordi Rimola, Alexandre Soler, Neus Llarch, Gemma Iserte, Ezequiel Mauro, Carmen Ayuso, Jose Rios, Jordi Bruix, Ramon
    Cancers.2023; 15(13): 3269.     CrossRef
  • Decoding Immune Signature to Detect the Risk for Early-Stage HCC Recurrence
    Aswathy R. Devan, Bhagyalakshmi Nair, Manu Kanjoormana Aryan, Vijayastelar B. Liju, Joel Joy Koshy, Bijo Mathew, Arun Valsan, Hoon Kim, Lekshmi R. Nath
    Cancers.2023; 15(10): 2729.     CrossRef
  • Predictive Factors of Treatment Outcomes After Percutaneous Radiofrequency Ablation of Hepatocellular Carcinoma in the Hepatocaval Confluence: A Propensity Score Matching Analysis
    Yanzhao Zhou, Kun Yuan, Yi Yang, Xiao Shan, Zemin Ji, Dezheng Zhou, Jingzhong Ouyang, Zhengzheng Wang, Qi Zhang, Jinxue Zhou, Qiang Li
    Academic Radiology.2023; 30: S92.     CrossRef
  • Risk factors for recurrence beyond Milan criteria after radiofrequency ablation in transplantable small hepatocellular carcinoma
    Weike Chu, Ping Li, Xue Wu, Peng Zhang, Hui Zhou, Bin Niu
    Revista Española de Enfermedades Digestivas.2022;[Epub]     CrossRef
  • Surgery versus radiofrequency ablation in patients with Child- Pugh class-A/single small (≤3 cm) hepatocellular carcinoma
    Jungnam Lee, Young-Joo Jin, Seung Kak Shin, Jung Hyun Kwon, Sang Gyune Kim, Young Ju Suh, Yujin Jeong, Jung Hwan Yu, Jin-Woo Lee, Oh Sang Kwon, Soon Woo Nahm, Young Seok Kim
    Clinical and Molecular Hepatology.2022; 28(2): 207.     CrossRef
  • Percutaneous thermal ablation combined with transcatheter arterial chemoembolization for hepatitis C virus-related hepatocellular carcinoma: Efficacy and survival
    Yu Sun, Honghai Zhang, Jiang Long, Yonghong Zhang, Jiasheng Zheng, Chunwang Yuan
    Frontiers in Oncology.2022;[Epub]     CrossRef
  • Non‐transplantable recurrence after percutaneous thermal ablation of ≤3‐cm HCC: Predictors and implications for treatment allocation
    Cecilia Gozzo, Margaux Hermida, Astrid Herrero, Fabrizio Panaro, Christophe Cassinotto, Azhar Meerun Mohamad, Eric Assenat, Chloé Guillot, Carole Allimant, Valentina Schembri, Antonio Basile, Sébastien Dharancy, José Ursic‐Bedoya, Boris Guiu
    Hepatology Communications.2022; 6(10): 2975.     CrossRef
  • Integrated Analysis Revealing the Role Of TET3-Mediated MUC13 Promoter Hypomethylation in Hepatocellular Carcinogenesis
    Ruijiao Kong, Hui Zhang, Yin Jia, Qiuhong Man, Shanrong Liu
    Epigenomics.2022; 14(24): 1579.     CrossRef
  • Risk factors of secondary infection/recurrence after ablation for liver cancers: A systemic review and meta-analysis
    Gang Yin, Nengwei Zhang, AMin BuHe, Wei Yan, Tianxiong Li, Jirun Peng
    Journal of Cancer Research and Therapeutics.2022; 18(5): 1352.     CrossRef
  • Risk Factors, Patterns, and Long-Term Survival of Recurrence After Radiofrequency Ablation With or Without Transarterial Chemoembolization for Hepatocellular Carcinoma
    Jingjun Huang, Wensou Huang, Yongjian Guo, Mingyue Cai, Jingwen Zhou, Liteng Lin, Kangshun Zhu
    Frontiers in Oncology.2021;[Epub]     CrossRef
  • Four types of tumor progression after microwave ablation of single hepatocellular carcinoma of ≤5 cm: incidence, risk factors and clinical significance
    Zhimei Huang, Zhixing Guo, Jiayan Ni, Mengxuan Zuo, Tianqi Zhang, Rong Ma, Chao An, Jinhua Huang
    International Journal of Hyperthermia.2021; 38(1): 1164.     CrossRef
  • Radiofrequency ablation with four electrodes as a building block for matrix radiofrequency ablation: Ex vivo liver experiments and finite element method modelling. Influence of electric and activation mode on coagulation size and geometry
    Stefaan Mulier, Ricardo Possebon, Yansheng Jiang, Jacques Jamart, Chong Wang, Yi Miao, Tongfu Yu, Kuirong Jiang, Yuanbo Feng, Guy Marchal, Luc Michel, Yicheng Ni
    Surgical Oncology.2020; 33: 145.     CrossRef
  • Long-term outcome of intraoperative radiofrequency ablation for hepatocellular carcinoma and its efficacy as a primary treatment
    Jongduk Kwon, Kwang-Sik Chun, In-Sang Song, Seok-Hwan Kim, Sunjong Han
    Annals of Hepato-Biliary-Pancreatic Surgery.2020; 24(1): 24.     CrossRef
  • Substantial risk of recurrence even after 5 recurrence-free years in early-stage hepatocellular carcinoma patients
    Jihye Kim, Wonseok Kang, Dong Hyun Sinn, Geum-Youn Gwak, Yong-Han Paik, Moon Seok Choi, Joon Hyeok Lee, Kwang Cheol Koh, Seung Woon Paik
    Clinical and Molecular Hepatology.2020; 26(4): 516.     CrossRef
  • Predicting outcomes for recurrent hepatocellular carcinoma within Milan criteria after complete radiofrequency ablation
    Hsin-Yeh Chen, Sheng-Nan Lu, Chao-Hung Hung, Jing-Houng Wang, Chien-Hung Chen, Yi-Hao Yen, Yuan-Hung Kuo, Kwong-Ming Kee, Tatsuo Kanda
    PLOS ONE.2020; 15(11): e0242113.     CrossRef
  • Feasibility, efficacy, and safety of percutaneous MR‐guided ablation of small (≤12 mm) hepatic malignancies
    Jakob Weiss, Rüdiger Hoffmann, Hansjoerg Rempp, David‐Emanuel Keβler, Philippe L. Pereira, Konstantin Nikolaou, Stephan Clasen
    Journal of Magnetic Resonance Imaging.2019; 49(2): 374.     CrossRef
  • Clinical outcomes of patients with a single hepatocellular carcinoma less than 5 cm treated with transarterial chemoembolization
    Min Young Baek, Jeong-Ju Yoo, Soung Won Jeong, Jae Young Jang, Yong Kwon Kim, Shin Ok Jeong, Sae Hwan Lee, Sang Gyune Kim, Sang-Woo Cha, Young Seok Kim, Young Deok Cho, Hong Soo Kim, Boo Sung Kim, Yong Jae Kim, Su Yeon Park
    The Korean Journal of Internal Medicine.2019; 34(6): 1223.     CrossRef
  • Outcomes of radiofrequency ablation as first-line therapy for hepatocellular carcinoma less than 3 cm in potentially transplantable patients
    Adam Doyle, Andre Gorgen, Hala Muaddi, Aloysious D. Aravinthan, Assaf Issachar, Oleg Mironov, Wei Zhang, John Kachura, Robert Beecroft, Sean P. Cleary, Anand Ghanekar, Paul D. Greig, Ian D. McGilvray, Markus Selzner, Mark S. Cattral, David R. Grant, Lesli
    Journal of Hepatology.2019; 70(5): 866.     CrossRef
  • Clinical and circulating biomarkers of survival and recurrence after radiofrequency ablation in patients with hepatocellular carcinoma
    Matteo Canale, Paola Ulivi, Francesco Giuseppe Foschi, Emanuela Scarpi, Serena De Matteis, Gabriele Donati, Giorgio Ercolani, Mario Scartozzi, Luca Faloppi, Alessandro Passardi, Emiliano Tamburini, Martina Valgiusti, Giorgia Marisi, Giovanni Luca Frassine
    Critical Reviews in Oncology/Hematology.2018; 129: 44.     CrossRef
  • A new scoring model predicting macroscopic vascular invasion of early-intermediate hepatocellular carcinoma
    Yao Liu, Le Sun, Fangyuan Gao, Xue Yang, Yuxin Li, Qun Zhang, Bingbing Zhu, Shuaishuai Niu, Yunyi Huang, Ying Hu, Ying Feng, Yuyong Jiang, Xianbo Wang
    Medicine.2018; 97(49): e13536.     CrossRef
  • Traitement ablatif pour cancer du rein : modalités d’évaluation pré-, per-, post-intervention et prise en charge adaptée
    J. Garnon, T. Tricard, R.L. Cazzato, X. Cathelineau, A. Gangi, H. Lang
    Progrès en Urologie.2017; 27(15): 971.     CrossRef
  • Editorial: rifaximin in cirrhosis—is this what we've been waiting for? Authors’ reply
    S. H. Kang, Y. B. Lee, J.‐H. Lee
    Alimentary Pharmacology & Therapeutics.2017; 46(10): 1017.     CrossRef
  • 12,378 View
  • 168 Download
  • 28 Web of Science
  • Crossref

Hepatic neoplasm

Transarterial chemoembolization versus resection for intermediate-stage (BCLC B) hepatocellular carcinoma
Jun Young Kim, Dong Hyun Sinn, Geum-Youn Gwak, Gyu-Seong Choi, Aldosri Meshal Saleh, Jae-Won Joh, Sung Ki Cho, Sung Wook Shin, Keumhee Chough Carriere, Joong Hyun Ahn, Yong-Han Paik, Moon Seok Choi, Joon Hyeok Lee, Kwang Cheol Koh, Seung Woon Paik
Clin Mol Hepatol 2016;22(2):250-258.
Published online June 25, 2016
DOI: https://doi.org/10.3350/cmh.2016.0015
Background/Aims
Several studies have suggested that surgical resection (SR) can provide a survival benefit over transarterial chemoembolization (TACE) for hepatocellular carcinoma (HCC) at the intermediate stage according to the Barcelona Clinic Liver Cancer (BCLC) staging system. However, the criteria for SR remain to be determined. This study compared the long-term outcome of intermediate-stage HCC patients treated by either TACE or SR as a primary treatment modality, with the aim of identifying the patient subgroup that gained a survival benefit by either modality.
Methods
In total, 277 BCLC intermediate-stage HCC patients treated by either TACE (N=225) or SR (N=52) were analyzed.
Results
The overall median survival time was significantly better for SR than TACE (61 vs. 30 months, P=0.002). Decisiontree analysis divided patients into seven nodes based on tumor size and number, serum alpha-fetoprotein (AFP) level, and Child-Pugh score, and these were then simplified into four subgroups (B1–B4) based on similarities in the overall hazard rate. SR provided a significant survival benefit in subgroup B2, characterized by ‘oligo’ (2–4) nodules of intermediate size (5–10 cm) when the AFP levels was <400 ng/ml, or ‘oligo’ (2–4) nodules of small to intermediate size (<10 cm) plus a Child-Pugh score of 5 when the AFP level was ≥400 ng/mL (median survival 73 vs. 28 months for SR vs. TACE respectively; P=0.014). The survival rate did not differ significantly between SR and TACE in the other subgroups (B1 and B3).
Conclusions
SR provided a survival benefit over TACE in intermediate-stage HCC, especially for patients meeting certain criteria. Re-establishing the criteria for optimal treatment modalities in this stage of HCC is needed to improve survival rates.

Citations

Citations to this article as recorded by  Crossref logo
  • Long-term results of surgical treatment in patients with intermediate stage (BCLC B) hepatocellular carcinoma: a single-center retrospective study
    B. I. Sakibov, D. V. Podluzhnyi, Yu. I. Patyutko, O. A. Egenov, N. E. Kudashkin
    Surgery and Oncology.2025; 15(2): 62.     CrossRef
  • Efficacy of therapies for intermediate-stage hepatocellular carcinoma: systematic review and network meta-analysis
    Shaoqi Zong, Yifan Yang, Zifei Yin, Lanyun Feng, Kun Wang, Hao Chen, Zhen Chen, Zhiqiang Meng, Yongqiang Hua
    Frontiers in Immunology.2025;[Epub]     CrossRef
  • Efficacy of postoperative adjuvant hepatic artery infusion chemotherapy for hepatocellular carcinoma in microvascular invasion: a propensity-matched score
    Xu Feng, Xinhua Wu, Kai Chen, Yupei Ao, Zhengrong Shi, Yixuan Gong
    Frontiers in Surgery.2025;[Epub]     CrossRef
  • Conversion Resection or Direct Resection for Patients with Intermediate-Stage Hepatocellular Carcinoma: A Multicentre Study
    Ying Zhou, Haiqing Wang, Jiayi Wu, Junyi Shen, Ji Ma, Qiu Li, Weixia Chen, Wusheng Lu, Xielin Feng, Maolin Yan, Tianfu Wen, Xiaoyun Zhang
    Liver Cancer.2025; : 1.     CrossRef
  • Identification of patients with favorable prognosis after resection in intermediate-stage-hepatocellular carcinoma
    Han Ah Lee, Minjong Lee, Jeong-Ju Yoo, Ho Soo Chun, Yewan Park, Hwi Young Kim, Tae Hun Kim, Yeon Seok Seo, Dong Hyun Sinn
    International Journal of Surgery.2024; 110(2): 1008.     CrossRef
  • Application of the Left Lateral Decubitus Position in Laparoscopic Right Posterior Lobectomy
    Dong-Fang Huang, Jian-Bo Xu, Ye-Mu Du, Ye-Bo Wang, Ding-Hua Zhou
    Surgical Laparoscopy, Endoscopy & Percutaneous Techniques.2024; 34(2): 178.     CrossRef
  • The role of resection in hepatocellular carcinoma BCLC stage B: A multi-institutional patient-level meta-analysis and systematic review
    Victor Lopez-Lopez, Fabian Kalt, Jian-Hong Zhong, Cristiano Guidetti, Paolo Magistri, Fabrizio Di Benedetto, Arndt Weinmann, Jens Mittler, Hauke Lang, Rohini Sharma, Mathew Vithayathil, Samir Tariq, Patricia Sánchez-Velázquez, Gianluca Rompianesi, Roberto
    Langenbeck's Archives of Surgery.2024;[Epub]     CrossRef
  • Prognostic performance of Hong Kong Liver Cancer with Barcelona Clinic Liver Cancer staging systems in hepatocellular carcinoma
    Mohamed Kohla, Reham Ashour, Hossam Taha, Osama El-Abd, Maher Osman, Mai Abozeid, Sally Waheed ELKhadry
    BMC Gastroenterology.2024;[Epub]     CrossRef
  • Intermediate hepatocellular carcinoma: new horizons and prospects for our patients
    Federica Lo Prinzi, Federico Rossari, Marianna Silletta, Silvia Foti, Silvia Camera, Francesco Vitiello, Elisabeth Amadeo, Francesco De Cobelli, Luca Aldrighetti, Margherita Rimini, Andrea Casadei-Gardini
    Expert Review of Gastroenterology & Hepatology.2024; 18(10): 661.     CrossRef
  • Surgical resection for large hepatocellular carcinoma and those beyond BCLC: systematic review with proposed management algorithm
    Saneya Pandrowala, Shraddha Patkar, Mahesh Goel, Darius Mirza, S. K. Mathur
    Langenbeck's Archives of Surgery.2023;[Epub]     CrossRef
  • Liver resection versus transarterial chemoembolisation for the treatment of intermediate hepatocellular carcinoma: a systematic review and meta-analysis
    Aleksandar Bogdanovic, Jelena Djokic Kovac, Predrag Zdujic, Uros Djindjic, Vladimir Dugalic
    International Journal of Surgery.2023; 109(5): 1439.     CrossRef
  • Efficacy and safety of lenvatinib–transcatheter arterial chemoembolisation sequential therapy followed by surgical resection for intermediate-stage hepatocellular carcinoma beyond Up-to-7 criteria: a study protocol for a multicentre, single-arm, prospecti
    Ko Oshita, Tsuyoshi Kobayashi, Yosuke Namba, Sotaro Fukuhara, Keiso Matsubara, Daisuke Takei, Ryosuke Nakano, Wataru Okamoto, Hiroshi Sakai, Naoki Tanimine, Takashi Nakahara, Shintaro Kuroda, Hiroyuki Tahara, Masahiro Ohira, Tomokazu Kawaoka, Kentaro Ide,
    BMJ Open.2023; 13(10): e073797.     CrossRef
  • A retrospective study of transarterial chemoembolization (TACE) combined with lenvatinib compared with TACE monotherapy for BCLC B2 stage hepatocellular carcinoma
    Junning Liu, Shu Yan, Guangnian Zhang, Linfeng Yang, Song Wei, Pengsheng Yi
    Oncology Letters.2023;[Epub]     CrossRef
  • Novel predictive nomograms based on aspartate aminotransferase‑to‑platelet ratio index for hepatocellular carcinoma with post‑operative adjuvant transarterial chemoembolization
    Qinghua Shu, Nannan Zhang, Jianbo Han, Xiaopeng Yan, Bowen Sha, Liang Zhao, Yongxiang Yi, Yufeng Zhang
    Oncology Letters.2023;[Epub]     CrossRef
  • Selecting the Best Approach for the Treatment of Multiple Non-Metastatic Hepatocellular Carcinoma
    Gianluca Cassese, Ho-Seong Han, Jai Young Cho, Hae-Won Lee, Boram Lee, Roberto Ivan Troisi
    Cancers.2022; 14(23): 5997.     CrossRef
  • The Clinical Value of Postoperative Transarterial Chemoembolization for Resectable Patients with Intermediate Hepatocellular Carcinoma After Radical Hepatectomy: a Propensity Score-Matching Study
    Lei Wang, Chunhong Xiao, Ren Wang, Jingbo Chen, Weiping Zhou, Jingfeng Liu, Nanping Lin, Kongying Lin
    Journal of Gastrointestinal Surgery.2021; 25(5): 1172.     CrossRef
  • Direct-Acting Antivirals Improve Treatment Outcomes in Patients with Hepatitis C Virus-Related Hepatocellular Carcinoma Treated with Transarterial Chemoembolization: A Nationwide, Multi-center, Retrospective Cohort Study
    Hye Kyung Hyun, Eun Ju Cho, Soo Young Park, Young Mi Hong, Soon Sun Kim, Hwi Young Kim, Nae-Yun Heo, Jung Gil Park, Dong Hyun Sinn, Wonseok Kang, Song Won Jeong, Myeong Jun Song, Hana Park, Danbi Lee, Yong Sun Lee, Sung Bum Cho, Chan Sik An, Hyung Jin Rhe
    Digestive Diseases and Sciences.2021; 66(7): 2427.     CrossRef
  • Development of a computed tomography-based radiomics nomogram for prediction of transarterial chemoembolization refractoriness in hepatocellular carcinoma
    Xiang-Ke Niu, Xiao-Feng He
    World Journal of Gastroenterology.2021; 27(2): 189.     CrossRef
  • Prognostic Value of Alpha-Fetoprotein in Patients Who Achieve a Complete Response to Transarterial Chemoembolization for Hepatocellular Carcinoma
    Jae Seung Lee, Young Eun Chon, Beom Kyung Kim, Jun Yong Park, Do Young Kim, Sang Hoon Ahn, Kwang-Hyub Han, Wonseok Kang, Moon Seok Choi, Geum-Youn Gwak, Yong-Han Paik, Joon Hyeok Lee, Kwang Cheol Koh, Seung Woon Paik, Hwi Young Kim, Tae Hun Kim, Kwon Yoo,
    Yonsei Medical Journal.2021; 62(1): 12.     CrossRef
  • Predictors of Complete Response in Patients with Hepatocellular Carcinoma Treated with Trans-Arterial Radioembolization
    Yuna Kim, Jae Seung Lee, Hye Won Lee, Beom Kyung Kim, Jun Yong Park, Do Young Kim, Sang Hoon Ahn, Seung Up Kim
    Current Oncology.2021; 28(1): 965.     CrossRef
  • Prediction of Patient Survival Following Hepatic Resection in Early-Stage Hepatocellular Carcinoma with Indexed Ratios of Aspartate Aminotransferase to Platelets: A Retrospective Cohort Study
    Jian Huang, Yun Yang, Yong Xia, Fu-Chen Liu, Lei Liu, Peng Zhu, Sheng-Xian Yuan, Fang-Ming Gu, Si-Yuan Fu, Wei-Ping Zhou, Hui Liu, Bei-Ge Jiang, Ze-Ya Pan
    Cancer Management and Research.2021; Volume 13: 1733.     CrossRef
  • Efficacy of Combined Therapy with Drug-Eluting Beads-Transcatheter Arterial Chemoembolization Followed by Conventional Transcatheter Arterial Chemoembolization for Unresectable Hepatocellular Carcinoma: A Multi-Center Study
    Asahiro Morishita, Joji Tani, Takako Nomura, Kei Takuma, Mai Nakahara, Kyoko Oura, Tomoko Tadokoro, Koji Fujita, Tingting Shi, Hiroki Yamana, Takanori Matsui, Tadayuki Takata, Takayuki Sanomura, Yoshihiro Nishiyama, Takashi Himoto, Tetsu Tomonari, Akio Mo
    Cancers.2021; 13(18): 4605.     CrossRef
  • An observational study on long‐term renal outcome in patients with chronic hepatitis B treated with tenofovir disoproxil fumarate
    Tae Seop Lim, Jae Seung Lee, Beom Kyung Kim, Hye Won Lee, Mi Young Jeon, Seung Up Kim, Jun Yong Park, Do Young Kim, Kwang‐Hyub Han, Sang Hoon Ahn
    Journal of Viral Hepatitis.2020; 27(3): 316.     CrossRef
  • Transarterial strategies for the treatment of unresectable hepatocellular carcinoma: A systematic review
    Biao Yang, Jie Liang, ZiYu Qu, FangYun Yang, ZhengYin Liao, HongFeng Gou, Gianfranco D. Alpini
    PLOS ONE.2020; 15(2): e0227475.     CrossRef
  • Appraisal of a Model to Estimate Survival in Ambulatory Patients with Hepatocellular Carcinoma Classified as Barcelona Clinic Liver Cancer Stage B
    Jeong-Ju Yoo, Su Jong Yu, Bora Lee, Eun Ju Cho, Jeong-Hoon Lee, Sang Gyune Kim, Yoon Jun Kim, Young Seok Kim, Jung-Hwan Yoon
    Gut and Liver.2020; 14(3): 377.     CrossRef
  • Proposal of a New Risk Score for Patients Treated with Transarterial Chemoembolization due to Recurrent Hepatocellular Carcinoma after Curative Resection: A Multicenter Study
    Mi Young Jeon, Beom Kyung Kim, Jun Yong Park, Do Young Kim, Sang Hoon Ahn, Kwang-Hyub Han, Jeong-Hoon Lee, Su Jong Yu, Yoon Jun Kim, Jung-Hwan Yoon, Eun Ju Cho, Seung Up Kim
    Gut and Liver.2020; 14(4): 477.     CrossRef
  • Comparison of Transcatheter Arterial Chemoembolization-Radiofrequency Ablation and Transcatheter Arterial Chemoembolization Alone for Advanced Hepatocellular Carcinoma with Macrovascular Invasion Using Propensity Score Analysis: A Retrospective Cohort Stu
    Yao Liu, Yuxin Li, Fangyuan Gao, Qun Zhang, Xue Yang, Bingbing Zhu, Shuaishuai Niu, Yunyi Huang, Ying Hu, Wei Li, Xianbo Wang
    Journal of Oncology.2020; 2020: 1.     CrossRef
  • Comparison of outcome between liver resection, radiofrequency ablation, and transarterial therapy for multiple small hepatocellular carcinoma within the Milan criteria
    Joo Hyun Oh, Dong Hyun Sinn, Gyu-Seong Choi, Jong Man Kim, Jae-Won Joh, Tae Wook Kang, Dongho Hyun, Wonseok Kang, Geum-Youn Gwak, Yong-Han Paik, Joon Hyeok Lee, Kwang Cheol Koh, Seung Woon Paik, Moon Seok Choi
    Annals of Surgical Treatment and Research.2020; 99(4): 238.     CrossRef
  • Is Transarterial Chemoembolization Only Treatment Option in Patients with Intermediate Stage of Hepatocellular Carcinoma?: in Perspectives of Surgery
    Ji Young Lim, Minjong Lee, Tae Hun Kim
    Journal of Liver Cancer.2020; 20(2): 113.     CrossRef
  • A Five‐Gene Signature for Recurrence Prediction of Hepatocellular Carcinoma Patients
    Zeyu Wang, Ningning Zhang, Jiayu Lv, Cuihua Ma, Jie Gu, Yawei Du, Yibo Qiu, Zhiguang Zhang, Man Li, Yong Jiang, Jianqiu Zhao, Huiqin Du, Zhiwei Zhang, Wei Lu, Yan Zhang, Luca Miele
    BioMed Research International.2020;[Epub]     CrossRef
  • Transarterial Chemoembolization Combined With Hepatectomy for the Treatment of Intermediate-Stage Hepatocellular Carcinoma
    Qunfang Zhou, Fei Tuo, Ruixia Li, Xiaohui Wang, Juncheng Wang, Zhimei Huang, Minshan Chen, Jinhua Huang
    Frontiers in Oncology.2020;[Epub]     CrossRef
  • The Modified Response Evaluation Criteria in Solid Tumors (RECIST) Yield a More Accurate Prognoses Than the RECIST 1.1 in Hepatocellular Carcinoma Treated with Transarterial Radioembolization
    Jae Seung Lee, Hong Jun Choi, Beom Kyung Kim, Jun Yong Park, Do Young Kim, Sang Hoon Ahn, Kwang-Hyub Han, Song-Ee Baek, Yong Eun Chung, Mi-Suk Park, Myeong-Jin Kim, Hyungjin Rhee, Seung Up Kim
    Gut and Liver.2020; 14(6): 765.     CrossRef
  • Comparison between hepatocellular carcinoma prognostic scores: A 10-year single-center experience and brief review of the current literature
    Michele Campigotto, Mauro Giuffrè, Anna Colombo, Alessia Visintin, Alessandro Aversano, Martina Budel, Flora Masutti, Cristiana Abazia, Lory Saveria Crocé
    World Journal of Hepatology.2020; 12(12): 1239.     CrossRef
  • Comparison of Partial Hepatectomy and Transarterial Chemoembolization in Intermediate-Stage Hepatocellular Carcinoma: A Systematic Review and Meta-Analysis
    Ismail Labgaa, Patrick Taffé, David Martin, Daniel Clerc, Myron Schwartz, Norihiro Kokudo, Alban Denys, Nermin Halkic, Nicolas Demartines, Emmanuel Melloul
    Liver Cancer.2020; 9(2): 138.     CrossRef
  • Refractoriness to transarterial chemoembolization in patients with recurrent hepatocellular carcinoma after curative resection
    Mi Young Jeon, Hye Soo Kim, Tae Seop Lim, Dai Hoon Han, Beom Kyung Kim, Jun Yong Park, Do Young Kim, Sang Hoon Ahn, Gi Hong Choi, Jin Sub Choi, Kwang-Hyub Han, Seung Up Kim, Gianfranco D. Alpini
    PLOS ONE.2019; 14(4): e0214613.     CrossRef
  • Clinical Relevance of Reductive Hepatectomy for Barcelona Clinic Liver Cancer Stages B and C Advanced Hepatocellular Carcinoma: A Single‐Center Experience of 102 Patients
    Shohei Komatsu, Masahiro Kido, Motofumi Tanaka, Kaori Kuramitsu, ·Daisuke Tsugawa, Masahide Awazu, Hidetoshi Gon, Hirochika Toyama, Kimihiko Ueno, Takumi Fukumoto
    World Journal of Surgery.2019; 43(10): 2571.     CrossRef
  • Hepatocellular carcinoma staging systems: Hong Kong liver cancer vs Barcelona clinic liver cancer in a Western population
    Laura Bainy Rodrigues de Freitas, Larisse Longo, Deivid Santos, Ivana Grivicich, Mário Reis Álvares-da-Silva
    World Journal of Hepatology.2019; 11(9): 689.     CrossRef
  • Surgical resection versus transarterial chemoembolization for BCLC intermediate stage hepatocellular carcinoma: a systematic review and meta-analysis
    Lei Liang, Hao Xing, Han Zhang, Jianhong Zhong, Chao Li, Wan Yee Lau, Mengchao Wu, Feng Shen, Tian Yang
    HPB.2018; 20(2): 110.     CrossRef
  • Can More Aggressive Treatment Improve Prognosis in Patients with Hepatocellular Carcinoma? A Direct Comparison of the Hong Kong Liver Cancer and Barcelona Clinic Liver Cancer Algorithms
    Young-Sun Lee, Yeon Seok Seo, Ji Hoon Kim, Juneyoung Lee, Hae Rim Kim, Yang Jae Yoo, Tae Suk Kim, Seong Hee Kang, Sang Jun Suh, Moon Kyung Joo, Young Kul Jung, Beom Jae Lee, Hyung Joon Yim, Jong Eun Yeon, Jae Seon Kim, Jong-Jae Park, Soon Ho Um, Young-Tae
    Gut and Liver.2018; 12(1): 94.     CrossRef
  • Chemoembolization related to good survival for selected patients with hepatocellular carcinoma invading segmental portal vein
    Jin Hyoung Kim, Ju Hyun Shim, Hyun‐Ki Yoon, Heung‐Kyu Ko, Jong Woo Kim, Dong Il Gwon
    Liver International.2018; 38(9): 1646.     CrossRef
  • Hepatic resection compared to chemoembolization in intermediate‐ to advanced‐stage hepatocellular carcinoma: A meta‐analysis of high‐quality studies
    Myung Han Hyun, Young‐Sun Lee, Ji Hoon Kim, Chan Uk Lee, Young Kul Jung, Yeon Seok Seo, Hyung Joon Yim, Jong Eun Yeon, Kwan Soo Byun
    Hepatology.2018; 68(3): 977.     CrossRef
  • Liver resection versus transarterial chemoembolization for the initial treatment of Barcelona Clinic Liver Cancer stage B hepatocellular carcinoma
    Biao Yang, Bo Zheng, MaoNan Yang, Zhu Zeng, FangYun Yang, Ji Pu, ChunLin Li, ZhengYin Liao
    Hepatology International.2018; 12(5): 417.     CrossRef
  • Impact of local tumor lesion treatments and preoperative indicators on the survival of patients with small hepatocellular carcinomas
    Yanyan Wei, Feng Dai, Yongxiang Yi, Wei Ye, Wei Zhao
    Oncology Letters.2018;[Epub]     CrossRef
  • Outcomes following liver resection for multinodular Barcelona Clinic Liver Cancer‑B hepatocellular carcinoma
    Satoshi Matsukuma, Kazuhiko Sakamoto, Yoshihiro Tokuhisa, Yukio Tokumitsu, Hiroto Matsui, Shinsuke Kanekiyo, Shinobu Tomochika, Michihisa Iida, Nobuaki Suzuki, Shigeru Takeda, Tomio Ueno, Hiroshi Wada, Shogo Kobayashi, Issei Saeki, Hidetoshi Eguchi, Masat
    Oncology Letters.2018;[Epub]     CrossRef
  • Therapeutic priorities for solitary large hepatocellular carcinoma in a hepatitis B virus endemic area; an analysis of a nationwide cancer registry database
    Young‐Joo Jin, Jin‐Woo Lee
    Journal of Surgical Oncology.2017; 115(4): 407.     CrossRef
  • Validity of the Barcelona Clinic Liver Cancer and Hong Kong Liver Cancer staging systems for hepatocellular carcinoma in Singapore
    Li Kim E. Selby, Rosanna X. Y. Tay, Winston W. L. Woon, Jee Keem Low, Wang Bei, Vishalkumar G. Shelat, Tony C. Y. Pang, Sameer P. Junnarkar
    Journal of Hepato-Biliary-Pancreatic Sciences.2017; 24(3): 143.     CrossRef
  • Survival Analysis of Single Large (>5 cm) Hepatocellular Carcinoma Patients: BCLC A versus B
    Yuri Cho, Dong Hyun Sinn, Su Jong Yu, Geum Youn Gwak, Ji Hoon Kim, Yang Jae Yoo, Dae Won Jun, Tae Yeob Kim, Hyo Young Lee, Eun Ju Cho, Jeong-Hoon Lee, Yoon Jun Kim, Jung-Hwan Yoon, Sheng-Nan Lu
    PLOS ONE.2016; 11(11): e0165722.     CrossRef
  • 15,182 View
  • 206 Download
  • 46 Web of Science
  • Crossref

Case Report

Benign liver tumors and cystic disease of liver

Intrahepatic bile duct adenoma in a patient with chronic hepatitis B accompanied by elevation of alpha-fetoprotein
Jem Ma Ahn, Yong-Han Paik, Jun Hee Lee, Ju Yeon Cho, Won Sohn, Geum-Youn Gwak, Moon Seok Choi, Joon Hyeok Lee, Kwang Cheol Koh, Seung Woon Paik, Byung Chul Yoo
Clin Mol Hepatol 2015;21(4):393-397.
Published online December 24, 2015
DOI: https://doi.org/10.3350/cmh.2015.21.4.393

A 51-year-old male patient with chronic hepatitis B was referred to our hospital due to a 1-cm liver nodule on ultrasonography. Alpha-fetoprotein (AFP) was slightly elevated. The nodule showed prolonged enhancement on dynamic liver magnetic resonance imaging and appeared as a hyperintensity on both diffusion-weighted and T2-weighted imaging. The nodule was followed up because it was small and typical findings of hepatocellular carcinoma (HCC) were not observed in the dynamic imaging investigations. However, liver contrast-enhanced ultrasonography performed 1 month later showed enhancement during the arterial phase and definite washout during the delayed phase. Also, AFP had increased to over 200 ng/mL even though AST and ALT were decreased after administering an antiviral agent. He was presumptively diagnosed as HCC and underwent liver segmentectomy. Microscopy findings of the specimen indicated bile duct adenoma. After resection, the follow-up AFP had decreased to within the normal range. This patient represents a case of bile duct adenoma with AFP elevation mimicking HCC on contrast-enhanced ultrasonography.

Citations

Citations to this article as recorded by  Crossref logo
  • Bile duct adenoma: imaging features and radiologic–pathologic correlation
    Ryoji Tatsumi, Shin Ichihara, Hirokazu Suii, Masakatsu Yamaguchi, Tomohiro Arakawa, Tomoaki Nakajima, Yasuaki Kuwata, Itaru Ozeki, Shuhei Hige, Joji Toyota, Yoshiyasu Karino
    Japanese Journal of Radiology.2020; 38(6): 561.     CrossRef
  • 14,145 View
  • 83 Download
  • 3 Web of Science
  • Crossref
Original Articles

Viral hepatitis

Static and dynamic prognostic factors for hepatitis-B-related acute-on-chronic liver failure
Jung Min Ha, Won Sohn, Ju Yeon Cho, Jeung Hui Pyo, Kyu Choi, Dong Hyun Sinn, Geum-Youn Gwak, Moon Seok Choi, Joon Hyeok Lee, Kwang Chul Koh, Seung Woon Paik, Byung Chul Yoo, Yong-Han Paik
Clin Mol Hepatol 2015;21(3):232-241.
Published online September 30, 2015
DOI: https://doi.org/10.3350/cmh.2015.21.3.232
Background/Aims

Hepatitis-B-related acute-on-chronic liver failure has a poor prognosis. However, the advent of potent oral antiviral agents means that some patients can now recover with medical treatment. We aimed to identify the prognostic factors for hepatitis-B-related acute-on-chronic liver failure including the initial as well as the dynamically changing clinical parameters during admission.

Methods

Sixty-seven patients were retrospectively enrolled from 2003 to 2012 at Samsung Medical Center. The patients were classified into three categories: Recovery group (n=23), Liver transplantation group (n=28), and Death group (n=16). The Liver transplantation and Death groups were combined into an Unfavorable prognosis group. We analyzed the prognostic factors including the Model for End-Stage Liver Disease (MELD) scores determined at 3-day intervals.

Results

A multivariable analysis showed that the unfavorable prognostic factors were a high initial MELD score (≥28) (odds ratio [OR] =6.64, p=0.015), moderate-to-severe ascites at admission (OR=6.71, P=0.012), and the aggravation of hepatic encephalopathy during hospitalization (≥grade III) (OR=15.41, P=0.013). Compared with the baseline level, significant reductions in the MELD scores were observed on the 7th day after admission in the Recovery group (P=0.016).

Conclusions

Dynamic changes in clinical parameters during admission are useful prognostic factors for hepatitis-B-related acute-on-chronic liver failure.

Citations

Citations to this article as recorded by  Crossref logo
  • Plasma galectin-3 can be considered as a non-invasive marker to predict the prognosis of ACLF patients with new typing
    Li Bai, Wang Lu, Qi Yang, Xiaoxuan Liu, Yu Chen, Zhongping Duan
    Scientific Reports.2025;[Epub]     CrossRef
  • Construction of a novel prognostic scoring model for HBV-ACLF liver failure based on dynamic data
    Qun Cai, Hao Wang, Mingyan Zhu, Yixin Xiao, Tingting Zhuo
    Scientific Reports.2024;[Epub]     CrossRef
  • PLT Counts as a Predictive Marker after Plasma Exchange in Patients with Hepatitis B Virus-Related Acute-on-Chronic Liver Failure
    Xue Li, Hao Li, Yucui Zhu, Huaqian Xu, Shanhong Tang
    Journal of Clinical Medicine.2023; 12(3): 851.     CrossRef
  • Falla hepática aguda sobre crónica: análisis de una serie de casos y revisión de la literatura
    Jhon Edwar García-Rueda, Ricardo Londoño-García, Tomás Marín-Cuartas, Juan Esteban Hernández-Abaunza, Sebastián Osorio-Rico, Angélica María Bermúdez-Flórez, Juan Carlos Restrepo-Gutiérrez
    Hepatología.2022; : 72.     CrossRef
  • KASL clinical practice guidelines for management of chronic hepatitis B

    Clinical and Molecular Hepatology.2022; 28(2): 276.     CrossRef
  • A dynamic prediction model for prognosis of acute-on-chronic liver failure based on the trend of clinical indicators
    Zhenjun Yu, Yu Zhang, Yingying Cao, Manman Xu, Shaoli You, Yu Chen, Bing Zhu, Ming Kong, Fangjiao Song, Shaojie Xin, Zhongping Duan, Tao Han
    Scientific Reports.2021;[Epub]     CrossRef
  • Clinical Course and Outcome Patterns of Acute-on-chronic Liver Failure: A Multicenter Retrospective Cohort Study
    Man-Man Xu, Ming Kong, Peng-Fei Yu, Ying-Ying Cao, Fang Liu, Bing Zhu, Yi-Zhi Zhang, Wang Lu, Huai-Bin Zou, Bin-Wei Duan, Shao-Li You, Shao-Jie Xin, Tao Han, Zhong-Ping Duan, Yu Chen
    Journal of Clinical and Translational Hepatology.2021; 000(000): 000.     CrossRef
  • KASL clinical practice guidelines for management of chronic hepatitis B

    Clinical and Molecular Hepatology.2019; 25(2): 93.     CrossRef
  • A Dynamic Model for Predicting Outcome in Patients with HBV Related Acute-On-Chronic Liver Failure
    Wei Lin, Jing Zhang, Xiaohui Liu, Hongqun Liu, Jinqiu He, Ming Li, Shuqin Zhang, Hong Chen, Changqing Zhang, Wenfang Wu, Chenggang Jin, Samuel S. Lee, Zhongping Duan, Yuexin Zhang
    Annals of Hepatology.2018; 17(3): 392.     CrossRef
  • 11,557 View
  • 96 Download
  • 9 Web of Science
  • Crossref

Liver fibrosis, cirrhosis, and portal hypertension

The comparison of esophageal variceal ligation plus propranolol versus propranolol alone for the primary prophylaxis of esophageal variceal bleeding
Dongmo Je, Yong-Han Paik, Geum-Youn Gwak, Moon Seok Choi, Joon Hyeok Lee, Kwang Cheol Koh, Seung Woon Paik, Byung Chul Yoo
Clin Mol Hepatol 2014;20(3):283-290.
Published online September 25, 2014
DOI: https://doi.org/10.3350/cmh.2014.20.3.283
Background/Aims

To investigate the efficacy and longterm outcome of esophageal variceal ligation (EVL) plus propranolol in comparison with propranolol alone for the primary prophylaxis of esophageal variceal bleeding.

Methods

A total of 504 patients were retrospectively enrolled in this study. 330 patients were in propranolol group (Gr1) and 174 patients were in EVL plus propranolol group (Gr2). The endpoints of this study were esophageal variceal bleeding and mortality. Association analyses were performed to evaluate bleeding and mortality between Gr1 and Gr2.

Results

EVL was more applied in patients with high risk, such as large-sized varices (F2 or F3) or positive red color signs. Total 38 patients had bleeds, 32 in Gr1 and 6 in Gr2. The cumulative probability of bleeding at 120 months was 13% in Gr1 versus 4% in Gr2 (P=0.04). The predictive factors of variceal bleeding were red color signs (OR 2.962, P=0.007) and the method of propranolol plus EVL (OR 0.160, P=0.000). 20 patients died in Gr1 and 12 in Gr2. Mortality rates are similar in the two groups compared, 6.7% in Gr1 and 6.9% in Gr2. The cumulative probability of mortality at 120 months was not significantly different in the two groups (7% in Gr1, 12% in Gr2, P=0.798). The prognostic factors for mortality were age over 50 (OR 5.496, P=0.002), Child-Pugh class B (OR 3.979, P=0.001), and Child-Pugh class C (OR 10.861, P=0.000).

Conclusions

EVL plus propranolol is more effective than propranolol alone in the prevention of the first variceal bleeding in patients with liver cirrhosis.

Citations

Citations to this article as recorded by  Crossref logo
  • Analysis of risk factors for hospital-acquired pneumonia in schizophrenia
    Yu-hang Chen, Cong-ying Ren, Yu Liao
    Frontiers in Psychiatry.2024;[Epub]     CrossRef
  • Combined Pharmacological and Endoscopic Treatment for Worsening Gastroesophageal Varices in Patients with Cirrhosis
    Veronica Pepe, Paolo Angeli, Marco Di Pascoli
    Clinical and Experimental Gastroenterology.2022; Volume 15: 59.     CrossRef
  • Nonsurgical Secondary Prophylaxis of Esophageal Variceal Bleeding in Cirrhotic Patients
    Liwei Jing, Qiumeng Zhang, Ziwei Chang, Hui Liu, Xuan Shi, Xingyu Li, Jing Wang, Yanbo Mo, Xiujing Zhang, Lizhuan Ma, Zhiting Li, Chao Zhang
    Journal of Clinical Gastroenterology.2021; 55(2): 159.     CrossRef
  • Influencing Factors of Hospital-Acquired Pneumonia Infection in the Middle-Aged and Elderly Patients With Schizophrenia
    Mi Yang, Qiwen Li, Chunzhi Wang, Li Li, Min Xu, Fei Yan, Wei Chen, Ying Wan
    Frontiers in Psychiatry.2021;[Epub]     CrossRef
  • Long-term outcome of endoscopic variceal band ligation of esophageal varices in patients with chronic liver disease
    Gautam Ray
    Indian Journal of Gastroenterology.2019; 38(1): 69.     CrossRef
  • Liver volume index predicts the risk of esophageal variceal hemorrhage in cirrhotic patients on propranolol prophylaxis
    Beom Hee Kim, Jung Wha Chung, Chung Seop Lee, Eun Sun Jang, Sook-Hyang Jeong, Nayoung Kim, Jin-Wook Kim
    The Korean Journal of Internal Medicine.2019; 34(6): 1233.     CrossRef
  • Carvedilol for reducing portal pressure in primary prophylaxis of variceal bleeding: a dose‐response study
    R. Schwarzer, D. Kivaranovic, R. Paternostro, M. Mandorfer, T. Reiberger, M. Trauner, M. Peck‐Radosavljevic, A. Ferlitsch
    Alimentary Pharmacology & Therapeutics.2018; 47(8): 1162.     CrossRef
  • Small Esophageal Varices in Patients with Cirrhosis—Should We Treat Them?
    Thomas Reiberger, Theresa Bucsics, Rafael Paternostro, Nikolaus Pfisterer, Florian Riedl, Mattias Mandorfer
    Current Hepatology Reports.2018; 17(4): 301.     CrossRef
  • Rifaximin and Propranolol Combination Therapy Is More Effective than Propranolol Monotherapy for the Reduction of Portal Pressure: An Open Randomized Controlled Pilot Study
    Yoo Li Lim, Moon Young Kim, Yoon Ok Jang, Soon Koo Baik, Sang Ok Kwon
    Gut and Liver.2017; 11(5): 702.     CrossRef
  • Changes in Cardiac Varices and Their Clinical Significance after Eradication of Esophageal Varices by Band Ligation
    Seung Woon Park, Yeon Seok Seo, Han Ah Lee, Sang Jung Park, Tae Hyung Kim, Jae Min Lee, Sang Jun Suh, Hyuk Soon Choi, Eun Sun Kim, Bora Keum, Young Kul Jung, Ji Hoon Kim, Hyonggin An, Hyung Joon Yim, Yoon Tae Jeen, Jong Eun Yeon, Hong Sik Lee, Hoon Jai Ch
    Canadian Journal of Gastroenterology and Hepatology.2016; 2016: 1.     CrossRef
  • 10,997 View
  • 93 Download
  • 10 Web of Science
  • Crossref

Comparison of usefulness of clinical diagnostic criteria for hepatocellular carcinoma in a hepatitis B endemic area
So Young Bae, Moon Seok Choi, Geum-Youn Gwak, Yong Han Paik, Joon Hyoek Lee, Kwang Cheol Koh, Seung Woon Paik, Byung Chul Yoo
Korean J Hepatol 2012;18(2):185-194.
Published online June 26, 2012
DOI: https://doi.org/10.3350/cmh.2012.18.2.185
Background/Aims

We compared the accuracy and usefulness of clinical diagnostic criteria for hepatocellular carcinoma in a hepatitis B virus (HBV)-endemic area.

Methods

We reviewed the medical records of 355 patients who had undergone liver resection or biopsy at our institution between January 2008 and December 2009. These patients were reevaluated using four noninvasive diagnostic criteria for hepatocellular carcinoma proposed by the European Association for the Study of the Liver (EASL), the American Association for the Study of Liver Diseases (AASLD), the Korean Liver Cancer Study Group and the National Cancer Center (KLCSG/NCC), and National Comprehensive Cancer Network (NCCN) guidelines.

Results

The overall sensitivity was highest using the KLCSG/NCC criteria (79.8%), followed by the AASLD (51.5%), EASL (38.4%), and NCCN (10.1%; P<0.001) criteria, whereas the specificity (84.5-98.3%) and positive predictive value (96.2-98.3%) were similar for all of the criteria. The KLCSG/NCC criteria had an acceptable false-positive rate and the highest sensitivity among all of the patients, including those positive for HBsAg, those without liver cancer, and those with a tumor of at least 2 cm.

Conclusions

The KLCSG/NCC and AASLD criteria exhibited the highest sensitivity, and all four guidelines had a high specificity among all of the patients. Based on the sensitivity and false-positive rate, the KLCSG/NCC criteria was the most useful in the majority of patients. Inclusion of HBV infection in the clinical diagnostic criteria for hepatocellular carcinoma would be reasonable and may lead to an improvement in the sensitivity, with acceptable false-positive rates, in HBV-endemic areas.

Citations

Citations to this article as recorded by  Crossref logo
  • Pragmatic Approach to Hepatocellular Carcinoma Diagnosis in High-Incidence, Resource-Limited Settings in Africa
    Gregory D. Kirk, Sara Nsibirwa, Jim K. Aizire, Redeat L. Assefa, Antonio Bandala-Jacques, Jackson Orem, Tongai Maponga, Moussa Seydi, Gilles Wandeler, Amir Mohareb, David L. Thomas, Fred Okuku, Emmanuelle Ochola, Ponsiano Ocama
    JCO Global Oncology.2025;[Epub]     CrossRef
  • Comparison of the diagnostic performance of imaging criteria for HCCs ≤ 3.0 cm on gadoxetate disodium-enhanced MRI
    Jieun Byun, Sang Hyun Choi, Jae Ho Byun, So Jung Lee, So Yeon Kim, Hyung Jin Won, Yong Moon Shin, Pyo-Nyun Kim
    Hepatology International.2020; 14(4): 534.     CrossRef
  • Non-invasive diagnostic criteria of hepatocellular carcinoma: Comparison of diagnostic accuracy of updated LI-RADS with clinical practice guidelines of OPTN-UNOS, AASLD, NCCN, EASL-EORTC, and KLSCG-NCC
    Burcu Erkan, Jeffrey Meier, Toshimasa J. Clark, Jeffrey Kaplan, Jeffrey R. Lambert, Samuel Chang, Isabelle Chemin
    PLOS ONE.2019; 14(12): e0226291.     CrossRef
  • 2014 Korean Liver Cancer Study Group-National Cancer Center Korea Practice Guideline for the Management of Hepatocellular Carcinoma

    Korean Journal of Radiology.2015; 16(3): 465.     CrossRef
  • 2014 KLCSG-NCC Korea Practice Guidelines for the Management of Hepatocellular Carcinoma: HCC Diagnostic Algorithm
    Jeong Min Lee, Joong-Won Park, Byung Ihn Choi
    Digestive Diseases.2014; 32(6): 764.     CrossRef
  • Status of Primary Liver Cancer Found through Routine Health Check-up
    Changhyun Lee, Jong In Yang, Hee Jin Byun, Jung Mook Kang, Seoungho Choi, Jeong Yoon Yim
    Journal of Korean Medical Science.2013; 28(10): 1449.     CrossRef
  • Noninvasive diagnostic criteria for hepatocellular carcinoma
    Han Chu Lee
    Clinical and Molecular Hepatology.2012; 18(2): 174.     CrossRef
  • 9,889 View
  • 75 Download
  • Crossref

Liver fibrosis, cirrhosis, and portal hypertension

A clinical predictor of varices and portal hypertensive gastropathy in patients with chronic liver disease
Yang Won Min, So Young Bae, Geum-Youn Gwak, Yong Han Paik, Moon Seok Choi, Joon Hyoek Lee, Seung Woon Paik, Byung Chul Yoo, Kwang Cheol Koh
Korean J Hepatol 2012;18(2):178-184.
Published online June 26, 2012
DOI: https://doi.org/10.3350/cmh.2012.18.2.178
Background/Aims

The aim of this study was to identify the parameters that could noninvasively predict the presence of esophageal/gastric varices and portal hypertensive gastropathy (PHG) in patients with chronic liver disease (CLD), and to determine the accuracy of those parameters.

Methods

We retrospectively analyzed 232 patients with CLD who underwent both upper endoscopy and liver CT within an interval of 3 months. The multidimensional index (M-Index) for spleen volume was obtained from the multiplication of splenic length, width, and thickness, as measured by computer tomography.

Results

The multivariate analysis revealed that platelet, albumin, and M-Index were independently associated with the presence of varices and PHG. We combined three independent parameters, and developed a varices and portal hypertensive gastropathy (VAP) scoring system (=[platelet count (/mm3)×albumin (g/dL)]/[M-Index (cm3)]). The area under the receiver operating characteristic curve of the VAP score was 0.850 (95% confidence interval, 0.801-0.899). The VAP cut-off value of 861 had a sensitivity of 85.3%, a positive likelihood ratio of 3.17, and a negative predictive value of 86.4%. For predicting high-risk lesions for bleeding, with a cut-off value of 861 the sensitivity was 92.0%, the positive likelihood ratio was 2.20, and the negative predictive value was 96.4%.

Conclusions

The VAP score can predict the presence of varices and PHG in patients with CLD and may increase the cost-benefit of screening endoscopy in the clinical practice setting. A prospective validation study is necessary in the future.

Citations

Citations to this article as recorded by  Crossref logo
  • Role of platelet counts to spleen length ratio and platelet-albumin to spleen length ratio as non-invasive predictors of esophageal varices in chronic liver disease patients: A cross-sectional study in Eastern India
    Y Sudheer Varma, Vijay Kumar, Ratnadeep Biswas, Vishnu Shankar Ojha, Divendu Bhushan, Ramesh Kumar, Rajeev Nayan Priyadarshi
    Journal of Family Medicine and Primary Care.2025; 14(7): 2987.     CrossRef
  • Role of non-invasive serological and CT imaging parameters in assessing portal hypertensive gastropathy severity
    Zhenzhen Liu, Bilun Ke, Shuyan Tan, Zhicheng Zhang, Dandan Shan, Jie Qin, Siwei Tan
    BMC Gastroenterology.2025;[Epub]     CrossRef
  • The impact of hepatic and splenic volumetric assessment in imaging for chronic liver disease: a narrative review
    Numan Kutaiba, William Chung, Mark Goodwin, Adam Testro, Gary Egan, Ruth Lim
    Insights into Imaging.2024;[Epub]     CrossRef
  • A Nomogram for Predicting Portal Hypertensive Gastropathy in Patients With Liver Cirrhosis: A Retrospective Analysis
    WenSheng Wang, ZhiYong Mu, GuangXi Zhu, Tao Wang, ShuJie Lai, Yan Guo, XinRu Yin, LiangZhi Wen, DongFeng Chen
    Frontiers in Medicine.2022;[Epub]     CrossRef
  • Risk factors for portal hypertensive gastropathy
    Ran Wu, Kunyi Liu, Chengyi Shi, Hui Tian, Na Wang
    BMC Gastroenterology.2022;[Epub]     CrossRef
  • Hemorheological Alteration in Patients Clinically Diagnosed with Chronic Liver Diseases
    Bohyun Jang, Ji Won Han, Pil Soo Sung, Jeong Won Jang, Si Hyun Bae, Jong Young Choi, Young I Cho, Seung Kew Yoon
    Journal of Korean Medical Science.2016; 31(12): 1943.     CrossRef
  • Portal hypertensive gastropathy: A systematic review of the pathophysiology, clinical presentation, natural history and therapy
    Mihajlo Gjeorgjievski
    World Journal of Hepatology.2016; 8(4): 231.     CrossRef
  • Comprehensive Predictors of Portal Pressure from Functional Liver Reserve in Patients Who Underwent Hepatectomy
    Atsushi Nanashima, Takafumi Abo, Junichi Arai, Tomoshi Tsuchiya, Takuro Miyazaki, Katsunori Takagi, Xiaohui Chen, Takeshi Nagayasu
    Indian Journal of Surgery.2015; 77(S3): 923.     CrossRef
  • Association of splenic MR elastographic findings with gastroesophageal varices in patients with chronic liver disease
    Hiroyuki Morisaka, Utaroh Motosugi, Shintaro Ichikawa, Katsuhiro Sano, Tomoaki Ichikawa, Nobuyuki Enomoto
    Journal of Magnetic Resonance Imaging.2015; 41(1): 117.     CrossRef
  • Prediction of portal pressure from intraoperative ultrasonography
    Atsushi Nanashima, Takafumi Abo, Junichi Arai, Tetsuro Tominaga, Katsunori Takagi, Koji Mochinaga, Katsuro Furukawa, Takeshi Nagayasu
    Journal of Surgical Research.2014; 192(2): 395.     CrossRef
  • The Quality of Care Provided to Patients With Varices in the Department of Veterans Affairs
    Paula M Buchanan, Jennifer R Kramer, Hashem B El-Serag, Steven M Asch, Youssef Assioun, Bruce R Bacon, Fasiha Kanwal
    American Journal of Gastroenterology.2014; 109(7): 934.     CrossRef
  • Constriction rate variation produced by partial ligation of the portal vein at pre-hepatic portal hypertension induced in rats
    Daren Athiê Boy RODRIGUES, Aline Riquena da SILVA, Leonardo Carvalho SERIGIOLLE, Ramiro de Sousa FIDALGO, Sergio San Gregorio FAVERO, Pedro Luiz Squilacci LEME
    ABCD. Arquivos Brasileiros de Cirurgia Digestiva (São Paulo).2014; 27(4): 280.     CrossRef
  • Aumento do volume do baço em modelo experimental de hipertensão portal pré-hepática em ratos
    Aline Riquena da Silva, Ricardo José Kriguer-Júnior, Leonardo Carvalho Serigiolle, Helbert Minuncio Pereira Gomes, Daren Athiê Boy Rodrigues, Pedro Luiz Squilacci Leme
    ABCD. Arquivos Brasileiros de Cirurgia Digestiva (São Paulo).2013; 26(3): 206.     CrossRef
  • 12,412 View
  • 75 Download
  • Crossref